Taking Estradiol and Progesterone Together

Systemic estradiol can stimulate the endometrium, the lining of the uterus. Continued estrogen exposure without adequate progestogen increases the risk of overgrowth and endometrial cancer. Progesterone is one medicine used to oppose that effect.

Progestogen is the broader term for medicines with this protective activity. A prescription can use micronized progesterone or another progestogen. The correct drug, dose, and number of treatment days matter. A cream advertised as progesterone cannot be assumed to provide equivalent protection.

After hysterectomy, estrogen alone is often used. Residual endometriosis or other circumstances may lead to a different recommendation. Low-dose local vaginal estrogen also has different prescribing considerations from systemic treatment.

Bijuva is a US-approved combined capsule for moderate to severe hot flashes in women with a uterus. Its current label lists 0.5 mg estradiol with 100 mg progesterone and 1 mg estradiol with 100 mg progesterone. It is taken once each evening with food.

Those strengths and instructions belong to Bijuva. Separate progesterone products can have different food instructions and schedules. NHS instructions for Utrogestan, for example, advise bedtime dosing at least two hours after food. Use the leaflet for the product actually dispensed.

A cyclic regimen adds the progestogen on specified days each month while systemic estrogen follows its prescription schedule. A withdrawal bleed can occur after the progestogen course ends. Continuous combined treatment supplies both hormones regularly and generally aims to avoid scheduled bleeding.

For an example of how specific the instructions can be, the US Prometrium label describes 200 mg at bedtime for 12 days of each 28-day cycle in postmenopausal women receiving conjugated estrogen tablets. That example does not define every regimen used alongside an estradiol patch.

Ask the prescriber to write the hormone names, doses, calendar days, and expected bleeding pattern. The amount of estrogen, menopausal stage, available products, and tolerance affect the plan. If one hormone is changed, confirm the instructions for the other.

Oral micronized progesterone can cause dizziness and drowsiness. Prometrium advises bedtime use and caution with driving or machinery. Report marked sedation, unsteadiness, or symptoms that continue into the next day.

Record whether headaches, mood changes, or bloating occur throughout the month or mainly on progesterone days. That timing helps a review of the drug and schedule. It does not establish the cause by itself.

If progesterone is difficult to tolerate, discuss an alternative protective regimen with the prescriber. Stopping it while continuing systemic estrogen can leave the uterine lining inadequately protected. Also check inactive ingredients: the cited Prometrium capsules contain peanut oil and are contraindicated with peanut allergy.

• Both dispensing labels and the calendar you use for doses or patch changes.
• The symptoms that improved and any effects that are difficult to tolerate.
• Bleeding dates, amount, and whether doses were missed.
• New medicines or supplements and any change in medical history.

NICE recommends prompt help for unscheduled bleeding beyond six months after starting systemic HRT or three months after changing it. Heavy or concerning bleeding should be reported earlier. The review should assess both the source of bleeding and whether the regimen supplies adequate protection.